Low-Dose IL-2 For The Reduction Of Vascular Inflammation In ACS -Clinical Outcomes & Follow-up Study

Launched by CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST · May 20, 2024

Keywords

ClinConnect Summary

The Low-Dose IL-2 For The Reduction Of Vascular Inflammation in Acute Coronary Syndromes study is a follow-up to the IVORY trial. Researchers believe that using a low dose of a medication called IL-2 may help reduce heart-related issues caused by inflammation, which is a factor in conditions like heart attacks. This study will track the health outcomes of patients who completed the previous trial to see if they experienced any serious heart events, such as heart attacks, strokes, or the need for surgery to improve blood flow.

To be eligible for this study, participants must have finished the full treatment of either low-dose IL-2 or a placebo (a dummy treatment) in the IVORY trial. They should also have agreed to allow their medical records to be reviewed. Those who did not want to participate or were removed from the IVORY trial for any reason cannot join this follow-up. Participants can expect the study to focus on gathering information about their heart health over time and any other serious health issues they may experience. This research is important as it may help improve treatments for heart conditions in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Participants who completed the full per-protocol treatment regime of low-dose IL2 or placebo having attended the final dosing visit in the IVORY trial. IVORY patients who previously consented to have their medical records inspected in the IVORY trial and who have already passed away at the commencement of IVORY-FINALE will also be included in analyses
• Exclusion Criteria:
• • Patients who decline participation
• • Patients who did not consent to being contacted about future research
• • Patients who were withdrawn from the IVORY trial for any reason

Trial Officials